249 related articles for article (PubMed ID: 31502857)
21. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2).
Berrevoets CA; Doesburg P; Steketee K; Trapman J; Brinkmann AO
Mol Endocrinol; 1998 Aug; 12(8):1172-83. PubMed ID: 9717843
[TBL] [Abstract][Full Text] [Related]
22. An androgen receptor N-terminal domain antagonist for treating prostate cancer.
Myung JK; Banuelos CA; Fernandez JG; Mawji NR; Wang J; Tien AH; Yang YC; Tavakoli I; Haile S; Watt K; McEwan IJ; Plymate S; Andersen RJ; Sadar MD
J Clin Invest; 2013 Jul; 123(7):2948-60. PubMed ID: 23722902
[TBL] [Abstract][Full Text] [Related]
23. Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium.
Lim M; Otto-Duessel M; He M; Su L; Nguyen D; Chin E; Alliston T; Jones JO
ACS Chem Biol; 2014 Mar; 9(3):692-702. PubMed ID: 24354286
[TBL] [Abstract][Full Text] [Related]
24. Phosphorylation of HSP90 by protein kinase A is essential for the nuclear translocation of androgen receptor.
Dagar M; Singh JP; Dagar G; Tyagi RK; Bagchi G
J Biol Chem; 2019 May; 294(22):8699-8710. PubMed ID: 30992362
[TBL] [Abstract][Full Text] [Related]
25. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
[TBL] [Abstract][Full Text] [Related]
26. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2).
Lim J; Ghadessy FJ; Abdullah AA; Pinsky L; Trifiro M; Yong EL
Mol Endocrinol; 2000 Aug; 14(8):1187-97. PubMed ID: 10935543
[TBL] [Abstract][Full Text] [Related]
27. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
Lakshmana G; Baniahmad A
Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
[TBL] [Abstract][Full Text] [Related]
28. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
[TBL] [Abstract][Full Text] [Related]
29. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
30. Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells.
Qin Z; Ou S; Xu L; Sorensen K; Zhang Y; Hu DP; Yang Z; Hu WY; Chen F; Prins GS
Chem Biol Drug Des; 2021 May; 97(5):1059-1078. PubMed ID: 33470049
[TBL] [Abstract][Full Text] [Related]
31. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.
Ponnusamy S; Coss CC; Thiyagarajan T; Watts K; Hwang DJ; He Y; Selth LA; McEwan IJ; Duke CB; Pagadala J; Singh G; Wake RW; Ledbetter C; Tilley WD; Moldoveanu T; Dalton JT; Miller DD; Narayanan R
Cancer Res; 2017 Nov; 77(22):6282-6298. PubMed ID: 28978635
[TBL] [Abstract][Full Text] [Related]
32. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
[TBL] [Abstract][Full Text] [Related]
33. Paradoxical androgen receptor regulation by small molecule enantiomers.
Patsch K; Liu C; Zapotoczny G; Sun Y; Sura H; Ung N; Sun RX; Haliday B; Yu C; Aljehani M; Lee JSH; Kashemirov BA; Agus DB; McKenna CE; Ruderman D
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33741738
[TBL] [Abstract][Full Text] [Related]
34. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC.
Ji Y; Zhang R; Han X; Zhou J
Eur J Med Chem; 2023 Feb; 247():115077. PubMed ID: 36587421
[TBL] [Abstract][Full Text] [Related]
35. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.
He B; Lanz RB; Fiskus W; Geng C; Yi P; Hartig SM; Rajapakshe K; Shou J; Wei L; Shah SS; Foley C; Chew SA; Eedunuri VK; Bedoya DJ; Feng Q; Minami T; Mitsiades CS; Frolov A; Weigel NL; Hilsenbeck SG; Rosen DG; Palzkill T; Ittmann MM; Song Y; Coarfa C; O'Malley BW; Mitsiades N
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18261-6. PubMed ID: 25489091
[TBL] [Abstract][Full Text] [Related]
36. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
[TBL] [Abstract][Full Text] [Related]
37. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
38. Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.
Pang JP; Shen C; Zhou WF; Wang YX; Shan LH; Chai X; Shao Y; Hu XP; Zhu F; Zhu DY; Xiao L; Xu L; Xu XH; Li D; Hou TJ
Acta Pharmacol Sin; 2022 Jan; 43(1):229-239. PubMed ID: 33767381
[TBL] [Abstract][Full Text] [Related]
39. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
40. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
McCarty MF; Hejazi J; Rastmanesh R
Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
